Anesthetic Cost Analysis With Desflurane in Automated Gas Control Mode

Safety Issues Clinical Trial

Official title: Anesthetic Cost Analysis With Desflurane in Automated Gas Control Mode With Maquet Flow-i Anaesthesia Machine

Status Completed

Clinical Trial Summary

Inhalation agents constitute the major part of anesthetic drug costs (20% - 25%) and a significant portion of the applied inhalation agents are thrown into the atmosphere through the waste gas system without being absorbed by the patient. The amount of waste gas is directly correlated to the fresh gas flow (FGF). Reducing the TGA during general anesthesia reduces the consumption of inhalant agents and contributes to the reduction of greenhouse gas pollution. Risks such as hypoxia, hypercapnia, inadequate depth of anesthesia and potential toxic gas accumulation were associated with low flow anesthesia, but the patient was provided with adequate safety by following pulse oximetry, capnography, FiO2 and anesthetic gas analysis. We aimed to perform anesthetic cost analysis and patient security in automated gas control mode (AGC).

Clinical Trial Description

After the ethical approvel 60 adult patients scheduled for hepatectomy will be taken to study. Patients will be monitored after they are taken to the operating room (ECG, NIBP, SpO2, Body Temp, BIS, NIRS, PVI, PI, ORI). After the anesthesia induction and tarakeal entubation, first twenty patient will take 300 mL fresh gas flow with AGC mode (group 1), Second twenty patient will take 600 mL fresh gas flow with AGC mode (group 2), third twenty patient will take 600 mL fresh gas flow with manually. Hemodynamic and gas consumption data will be recorded. An operating room will be reserved for this study. ;

Related Conditions & MeSH terms

• Safety Issues

• NCT number: NCT03465475
• Study type: Observational
• Source: Inonu University
• Status: Completed
• Start date: July 1, 2018
• Completion date: March 1, 2021